Tempus AI, Inc. (TEM) acquires Paige, a digital pathology AI company, for $81.25 million. Paige, founded in 2017, has the first FDA-cleared AI application in pathology, aiding cancer detection and precision medicine. With this acquisition, Tempus gains access to 7 million pathology slide images and diverse data sets from 45 countries.
Tempus AI, Inc. (TEM) utilizes AI to personalize patient care and improve healthcare outcomes. The company collects and analyzes vast patient data to create a comprehensive library of information. The acquisition of Paige accelerates Tempus’ efforts in building the largest foundation model in oncology.
Tempus AI, Inc. (NASDAQ: TEM) is considered one of the best Robinhood stocks to buy. The company’s focus on advancing precision medicine through AI technology has garnered attention. While TEM shows potential, other AI stocks may offer greater upside. Investors looking for undervalued AI stocks can explore different options.

Read more at Yahoo Finance: Tempus AI, Inc. (TEM) Expands into Digital Pathology with Paige Acquisition